A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome.

A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome.
复制标题

针对Hutchinson-Gilford Progeria综合征的有针对性的反义治疗方法。

DOI:
10.1038/s41591-021-01274-0
复制
发表时间:
2021-03
期刊:
影响因子:
82.9
通讯作者:
Collins, Francis S.
Collins, Francis S.
中科院分区:
医学1区
文献类型:
--
作者:
Erdos, Michael R.;Cabral, Wayne A.;Tavarez, Urraca L.;Cao, Kan;Gvozdenovic-Jeremic, Jelena;Narisu, Narisu;Zerfas, Patricia M.;Crumley, Stacy;Boku, Yoseph;Hanson, Gunnar;Mourich, Dan V.;Kole, Ryszard;Eckhaus, Michael A.;Gordon, Leslie B.;Collins, Francis S.

文献摘要

参考文献

被引文献

相似文献

Hutchinson-Gilford早老综合征(HGPS)是一种罕见的加速衰老疾病,其特征是心肌梗死或中风导致的过早死亡。它是由LMNA基因中的从头单核苷酸突变引起的,该突变激活了隐蔽剪接供体位点,导致产生一种毒性形式的核纤层蛋白A,称为早老蛋白。在这里,我们提出了一个潜在的遗传治疗策略,利用反义肽共轭磷酰二胺吗啉寡聚体(PPMO),以阻止致病性剪接的突变体转录。在几种候选物中,PPMO SRP-2001提供了患者成纤维细胞中早老蛋白转录物的最显著降低。将SRP-2001静脉内递送至HGPS转基因小鼠模型产生主动脉中早老蛋白转录物的显著减少,主动脉是HGPS中特别关键的靶组织。SRP-2001的长期连续治疗使寿命延长61.6%,并挽救了大动脉中的血管平滑肌细胞损失。这些结果为进行人体试验提供了依据。
Hutchinson–Gilford progeria syndrome (HGPS) is a rare accelerated aging disorder characterized by premature death from myocardial infarction or stroke. It is caused by de novo single-nucleotide mutations in the LMNA gene that activate a cryptic splice donor site, resulting in the production of a toxic form of lamin A, which is termed progerin. Here we present a potential genetic therapeutic strategy that utilizes antisense peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) to block pathogenic splicing of mutant transcripts. Of several candidates, PPMO SRP-2001 provided the most significant decrease in progerin transcripts in patient fibroblasts. Intravenous delivery of SRP-2001 to a transgenic mouse model of HGPS produced significant reduction of progerin transcripts in the aorta, a particularly critical target tissue in HGPS. Long-term continuous treatment with SRP-2001 yielded a 61.6% increase in lifespan and rescue of vascular smooth muscle cell loss in large arteries. These results provide a rationale for proceeding to human trials.
DOI: 10.1091/mbc.e13-11-0644
发表时间: 2014-04
影响因子: 3.3
作者:
Guo Y;Kim Y;Shimi T;Goldman RD;Zheng Y
通讯作者: Zheng Y
DOI: 10.1091/mbc.e11-10-0884
发表时间: 2012-06
影响因子: 3.3
作者:
Freund A;Laberge RM;Demaria M;Campisi J
通讯作者: Campisi J
DOI: 10.1073/pnas.1906713117
发表时间: 2020-06-02
影响因子: 11.1
作者:
Cubria, Maria B.;Suarez, Sebastian;Nazarian, Ara
通讯作者: Nazarian, Ara
DOI: 10.1126/scitranslmed.3002847
发表时间: 2011-10-26
影响因子: 17.1
作者:
Osorio, Fernando G.;Navarro, Claire L.;Lopez-Otin, Carlos
通讯作者: Lopez-Otin, Carlos
DOI: 10.1126/scitranslmed.3002346
发表时间: 2011-06-29
影响因子: 17.1
作者:
Cao, Kan;Graziotto, John J.;Collins, Francis S.
通讯作者: Collins, Francis S.